ReviewCancer immunology, immunotherapy : CII2011
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
Review in Cancer immunology, immunotherapy : CII, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02649829 (First-line Immunotherapy Using Wilms' Tumor Protein 1), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions.Cancers · 2023Review
- Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience.Thoracic cancer · 2022Article
- Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.Cancers · 2022Article
- Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis.Cancers · 2021Review
- Review
- A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.Cancer discovery · 2021Article
- CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.Lung cancer (Amsterdam, Netherlands) · 2021Review
- Immunotherapy in malignant pleural mesothelioma: a review of literature data.Translational lung cancer research · 2021Review
- Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.Frontiers in oncology · 2019Review
- Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.Cancer immunology, immunotherapy : CII · 2018Review
- Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.International journal of molecular sciences · 2018Review
- Evaluating the effect of immune cells on the outcome of patients with mesothelioma.British journal of cancer · 2017Article
- Novel insights into mesothelioma biology and implications for therapy.Nature reviews. Cancer · 2017Review
- Overview of treatment related complications in malignant pleural mesothelioma.Annals of translational medicine · 2017Review
- Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Scientific reports · 2016Article
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.Oncoimmunology · 2015Article
- CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?Cancer immunology, immunotherapy : CII · 2015Review
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Science translational medicine · 2014Article
- The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.Oncoimmunology · 2014Article
- Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.Cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive, primary pleural malignancy with poor prognosis, hypothesized to originate from a chronic inflammatory state within the pleura. Similar to what has been observed in other solid tumors (melanoma, ovarian and colorectal cancer), clinical and pre-clinical MPM investigations have correlated anti-tumor immune responses with improved survival. As such, a better understanding of the complex MPM tumor microenvironment is imperative in strategizing successful immunotherapies. Herein, we review the immune responses vital to the development and progression of MPM, as well as assess the role of immunomodulatory therapies, highlighting recent pre-clinical and clinical immunotherapy investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.